- Home
- RM vs AVIR Comparison
RM vs AVIR Comparison
Compare RM & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RM
- AVIR
- Stock Information
- Founded
- RM 1987
- AVIR 2012
- Country
- RM United States
- AVIR United States
- Employees
- RM N/A
- AVIR N/A
- Industry
- RM Finance: Consumer Services
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- RM Finance
- AVIR Health Care
- Exchange
- RM Nasdaq
- AVIR Nasdaq
- Market Cap
- RM 291.2M
- AVIR 276.9M
- IPO Year
- RM 2012
- AVIR 2020
- Fundamental
- Price
- RM $29.69
- AVIR $3.25
- Analyst Decision
- RM Hold
- AVIR Hold
- Analyst Count
- RM 3
- AVIR 1
- Target Price
- RM $31.50
- AVIR $6.88
- AVG Volume (30 Days)
- RM 26.9K
- AVIR 178.7K
- Earning Date
- RM 11-06-2024
- AVIR 11-07-2024
- Dividend Yield
- RM 4.06%
- AVIR N/A
- EPS Growth
- RM N/A
- AVIR N/A
- EPS
- RM 2.41
- AVIR N/A
- Revenue
- RM $556,726,000.00
- AVIR N/A
- Revenue This Year
- RM $13.14
- AVIR N/A
- Revenue Next Year
- RM $5.03
- AVIR N/A
- P/E Ratio
- RM $12.44
- AVIR N/A
- Revenue Growth
- RM 6.00
- AVIR N/A
- 52 Week Low
- RM $20.50
- AVIR $2.81
- 52 Week High
- RM $34.15
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- RM 46.30
- AVIR 44.03
- Support Level
- RM $28.94
- AVIR $3.10
- Resistance Level
- RM $30.43
- AVIR $3.48
- Average True Range (ATR)
- RM 1.18
- AVIR 0.13
- MACD
- RM 0.01
- AVIR -0.01
- Stochastic Oscillator
- RM 27.66
- AVIR 29.52
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).